img

Global Oncology Biosimilars Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Oncology Biosimilars Market Research Report 2024

Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.
According to Mr Accuracy reports’s new survey, global Oncology Biosimilars market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oncology Biosimilars market research.
Key companies engaged in the Oncology Biosimilars industry include Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd and Apotex, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % value of Oncology Biosimilars were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Oncology Biosimilars market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oncology Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Celltrion
Biocon
Dr. Reddy’s Laboratories
STADA Arzneimittel AG
Intas Pharmaceuticals
Pfizer
Sandoz International
Teva Pharmaceutical Industries Ltd
Apotex
BIOCAD
Segment by Type
Monoclonal Antibody
Hematopoietic Agents
G-CSF
Others

Segment by Application


Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Oncology Biosimilars report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Biosimilars Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 Monoclonal Antibody
1.2.3 Hematopoietic Agents
1.2.4 G-CSF
1.2.5 Others
1.3 Market by Application
1.3.1 Global Oncology Biosimilars Market Growth by Application: 2018 VS 2024 VS 2034
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Biosimilars Market Perspective (2018-2034)
2.2 Oncology Biosimilars Growth Trends by Region
2.2.1 Global Oncology Biosimilars Market Size by Region: 2018 VS 2024 VS 2034
2.2.2 Oncology Biosimilars Historic Market Size by Region (2018-2023)
2.2.3 Oncology Biosimilars Forecasted Market Size by Region (2024-2034)
2.3 Oncology Biosimilars Market Dynamics
2.3.1 Oncology Biosimilars Industry Trends
2.3.2 Oncology Biosimilars Market Drivers
2.3.3 Oncology Biosimilars Market Challenges
2.3.4 Oncology Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Biosimilars Players by Revenue
3.1.1 Global Top Oncology Biosimilars Players by Revenue (2018-2023)
3.1.2 Global Oncology Biosimilars Revenue Market Share by Players (2018-2023)
3.2 Global Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncology Biosimilars Revenue
3.4 Global Oncology Biosimilars Market Concentration Ratio
3.4.1 Global Oncology Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Biosimilars Revenue in 2024
3.5 Oncology Biosimilars Key Players Head office and Area Served
3.6 Key Players Oncology Biosimilars Product Solution and Service
3.7 Date of Enter into Oncology Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Biosimilars Breakdown Data by Type
4.1 Global Oncology Biosimilars Historic Market Size by Type (2018-2023)
4.2 Global Oncology Biosimilars Forecasted Market Size by Type (2024-2034)
5 Oncology Biosimilars Breakdown Data by Application
5.1 Global Oncology Biosimilars Historic Market Size by Application (2018-2023)
5.2 Global Oncology Biosimilars Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Oncology Biosimilars Market Size (2018-2034)
6.2 North America Oncology Biosimilars Market Growth Rate by Country: 2018 VS 2024 VS 2034
6.3 North America Oncology Biosimilars Market Size by Country (2018-2023)
6.4 North America Oncology Biosimilars Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncology Biosimilars Market Size (2018-2034)
7.2 Europe Oncology Biosimilars Market Growth Rate by Country: 2018 VS 2024 VS 2034
7.3 Europe Oncology Biosimilars Market Size by Country (2018-2023)
7.4 Europe Oncology Biosimilars Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncology Biosimilars Market Size (2018-2034)
8.2 Asia-Pacific Oncology Biosimilars Market Growth Rate by Region: 2018 VS 2024 VS 2034
8.3 Asia-Pacific Oncology Biosimilars Market Size by Region (2018-2023)
8.4 Asia-Pacific Oncology Biosimilars Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncology Biosimilars Market Size (2018-2034)
9.2 Latin America Oncology Biosimilars Market Growth Rate by Country: 2018 VS 2024 VS 2034
9.3 Latin America Oncology Biosimilars Market Size by Country (2018-2023)
9.4 Latin America Oncology Biosimilars Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Biosimilars Market Size (2018-2034)
10.2 Middle East & Africa Oncology Biosimilars Market Growth Rate by Country: 2018 VS 2024 VS 2034
10.3 Middle East & Africa Oncology Biosimilars Market Size by Country (2018-2023)
10.4 Middle East & Africa Oncology Biosimilars Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Celltrion
11.1.1 Celltrion Company Detail
11.1.2 Celltrion Business Overview
11.1.3 Celltrion Oncology Biosimilars Introduction
11.1.4 Celltrion Revenue in Oncology Biosimilars Business (2018-2023)
11.1.5 Celltrion Recent Development
11.2 Biocon
11.2.1 Biocon Company Detail
11.2.2 Biocon Business Overview
11.2.3 Biocon Oncology Biosimilars Introduction
11.2.4 Biocon Revenue in Oncology Biosimilars Business (2018-2023)
11.2.5 Biocon Recent Development
11.3 Dr. Reddy’s Laboratories
11.3.1 Dr. Reddy’s Laboratories Company Detail
11.3.2 Dr. Reddy’s Laboratories Business Overview
11.3.3 Dr. Reddy’s Laboratories Oncology Biosimilars Introduction
11.3.4 Dr. Reddy’s Laboratories Revenue in Oncology Biosimilars Business (2018-2023)
11.3.5 Dr. Reddy’s Laboratories Recent Development
11.4 STADA Arzneimittel AG
11.4.1 STADA Arzneimittel AG Company Detail
11.4.2 STADA Arzneimittel AG Business Overview
11.4.3 STADA Arzneimittel AG Oncology Biosimilars Introduction
11.4.4 STADA Arzneimittel AG Revenue in Oncology Biosimilars Business (2018-2023)
11.4.5 STADA Arzneimittel AG Recent Development
11.5 Intas Pharmaceuticals
11.5.1 Intas Pharmaceuticals Company Detail
11.5.2 Intas Pharmaceuticals Business Overview
11.5.3 Intas Pharmaceuticals Oncology Biosimilars Introduction
11.5.4 Intas Pharmaceuticals Revenue in Oncology Biosimilars Business (2018-2023)
11.5.5 Intas Pharmaceuticals Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Oncology Biosimilars Introduction
11.6.4 Pfizer Revenue in Oncology Biosimilars Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Sandoz International
11.7.1 Sandoz International Company Detail
11.7.2 Sandoz International Business Overview
11.7.3 Sandoz International Oncology Biosimilars Introduction
11.7.4 Sandoz International Revenue in Oncology Biosimilars Business (2018-2023)
11.7.5 Sandoz International Recent Development
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Teva Pharmaceutical Industries Ltd Company Detail
11.8.2 Teva Pharmaceutical Industries Ltd Business Overview
11.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Introduction
11.8.4 Teva Pharmaceutical Industries Ltd Revenue in Oncology Biosimilars Business (2018-2023)
11.8.5 Teva Pharmaceutical Industries Ltd Recent Development
11.9 Apotex
11.9.1 Apotex Company Detail
11.9.2 Apotex Business Overview
11.9.3 Apotex Oncology Biosimilars Introduction
11.9.4 Apotex Revenue in Oncology Biosimilars Business (2018-2023)
11.9.5 Apotex Recent Development
11.10 BIOCAD
11.10.1 BIOCAD Company Detail
11.10.2 BIOCAD Business Overview
11.10.3 BIOCAD Oncology Biosimilars Introduction
11.10.4 BIOCAD Revenue in Oncology Biosimilars Business (2018-2023)
11.10.5 BIOCAD Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Oncology Biosimilars Market Size Growth Rate by Type (US$ Million): 2018 VS 2024 VS 2034
Table 2. Key Players of Monoclonal Antibody
Table 3. Key Players of Hematopoietic Agents
Table 4. Key Players of G-CSF
Table 5. Key Players of Others
Table 6. Global Oncology Biosimilars Market Size Growth by Application (US$ Million): 2018 VS 2024 VS 2034
Table 7. Global Oncology Biosimilars Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 8. Global Oncology Biosimilars Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Oncology Biosimilars Market Share by Region (2018-2023)
Table 10. Global Oncology Biosimilars Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 11. Global Oncology Biosimilars Market Share by Region (2024-2034)
Table 12. Oncology Biosimilars Market Trends
Table 13. Oncology Biosimilars Market Drivers
Table 14. Oncology Biosimilars Market Challenges
Table 15. Oncology Biosimilars Market Restraints
Table 16. Global Oncology Biosimilars Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Oncology Biosimilars Market Share by Players (2018-2023)
Table 18. Global Top Oncology Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Biosimilars as of 2024)
Table 19. Ranking of Global Top Oncology Biosimilars Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Oncology Biosimilars Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Oncology Biosimilars Product Solution and Service
Table 23. Date of Enter into Oncology Biosimilars Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Oncology Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Oncology Biosimilars Revenue Market Share by Type (2018-2023)
Table 27. Global Oncology Biosimilars Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 28. Global Oncology Biosimilars Revenue Market Share by Type (2024-2034)
Table 29. Global Oncology Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Oncology Biosimilars Revenue Market Share by Application (2018-2023)
Table 31. Global Oncology Biosimilars Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 32. Global Oncology Biosimilars Revenue Market Share by Application (2024-2034)
Table 33. North America Oncology Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 34. North America Oncology Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Oncology Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 36. Europe Oncology Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 37. Europe Oncology Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Oncology Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 39. Asia-Pacific Oncology Biosimilars Market Size Growth Rate by Region (US$ Million): 2018 VS 2024 VS 2034
Table 40. Asia-Pacific Oncology Biosimilars Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Oncology Biosimilars Market Size by Region (2024-2034) & (US$ Million)
Table 42. Latin America Oncology Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 43. Latin America Oncology Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Oncology Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Oncology Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 46. Middle East & Africa Oncology Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Oncology Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 48. Celltrion Company Detail
Table 49. Celltrion Business Overview
Table 50. Celltrion Oncology Biosimilars Product
Table 51. Celltrion Revenue in Oncology Biosimilars Business (2018-2023) & (US$ Million)
Table 52. Celltrion Recent Development
Table 53. Biocon Company Detail
Table 54. Biocon Business Overview
Table 55. Biocon Oncology Biosimilars Product
Table 56. Biocon Revenue in Oncology Biosimilars Business (2018-2023) & (US$ Million)
Table 57. Biocon Recent Development
Table 58. Dr. Reddy’s Laboratories Company Detail
Table 59. Dr. Reddy’s Laboratories Business Overview
Table 60. Dr. Reddy’s Laboratories Oncology Biosimilars Product
Table 61. Dr. Reddy’s Laboratories Revenue in Oncology Biosimilars Business (2018-2023) & (US$ Million)
Table 62. Dr. Reddy’s Laboratories Recent Development
Table 63. STADA Arzneimittel AG Company Detail
Table 64. STADA Arzneimittel AG Business Overview
Table 65. STADA Arzneimittel AG Oncology Biosimilars Product
Table 66. STADA Arzneimittel AG Revenue in Oncology Biosimilars Business (2018-2023) & (US$ Million)
Table 67. STADA Arzneimittel AG Recent Development
Table 68. Intas Pharmaceuticals Company Detail
Table 69. Intas Pharmaceuticals Business Overview
Table 70. Intas Pharmaceuticals Oncology Biosimilars Product
Table 71. Intas Pharmaceuticals Revenue in Oncology Biosimilars Business (2018-2023) & (US$ Million)
Table 72. Intas Pharmaceuticals Recent Development
Table 73. Pfizer Company Detail
Table 74. Pfizer Business Overview
Table 75. Pfizer Oncology Biosimilars Product
Table 76. Pfizer Revenue in Oncology Biosimilars Business (2018-2023) & (US$ Million)
Table 77. Pfizer Recent Development
Table 78. Sandoz International Company Detail
Table 79. Sandoz International Business Overview
Table 80. Sandoz International Oncology Biosimilars Product
Table 81. Sandoz International Revenue in Oncology Biosimilars Business (2018-2023) & (US$ Million)
Table 82. Sandoz International Recent Development
Table 83. Teva Pharmaceutical Industries Ltd Company Detail
Table 84. Teva Pharmaceutical Industries Ltd Business Overview
Table 85. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product
Table 86. Teva Pharmaceutical Industries Ltd Revenue in Oncology Biosimilars Business (2018-2023) & (US$ Million)
Table 87. Teva Pharmaceutical Industries Ltd Recent Development
Table 88. Apotex Company Detail
Table 89. Apotex Business Overview
Table 90. Apotex Oncology Biosimilars Product
Table 91. Apotex Revenue in Oncology Biosimilars Business (2018-2023) & (US$ Million)
Table 92. Apotex Recent Development
Table 93. BIOCAD Company Detail
Table 94. BIOCAD Business Overview
Table 95. BIOCAD Oncology Biosimilars Product
Table 96. BIOCAD Revenue in Oncology Biosimilars Business (2018-2023) & (US$ Million)
Table 97. BIOCAD Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oncology Biosimilars Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Oncology Biosimilars Market Share by Type: 2024 VS 2034
Figure 3. Monoclonal Antibody Features
Figure 4. Hematopoietic Agents Features
Figure 5. G-CSF Features
Figure 6. Others Features
Figure 7. Global Oncology Biosimilars Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Oncology Biosimilars Market Share by Application: 2024 VS 2034
Figure 9. Retail Pharmacies Case Studies
Figure 10. Hospital Pharmacy Case Studies
Figure 11. Online Pharmacy Case Studies
Figure 12. Oncology Biosimilars Report Years Considered
Figure 13. Global Oncology Biosimilars Market Size (US$ Million), Year-over-Year: 2018-2034
Figure 14. Global Oncology Biosimilars Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 15. Global Oncology Biosimilars Market Share by Region: 2024 VS 2034
Figure 16. Global Oncology Biosimilars Market Share by Players in 2024
Figure 17. Global Top Oncology Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Biosimilars as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Oncology Biosimilars Revenue in 2024
Figure 19. North America Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 20. North America Oncology Biosimilars Market Share by Country (2018-2034)
Figure 21. United States Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 22. Canada Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 23. Europe Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 24. Europe Oncology Biosimilars Market Share by Country (2018-2034)
Figure 25. Germany Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 26. France Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 27. U.K. Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 28. Italy Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 29. Russia Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 30. Nordic Countries Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 31. Asia-Pacific Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 32. Asia-Pacific Oncology Biosimilars Market Share by Region (2018-2034)
Figure 33. China Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 34. Japan Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 35. South Korea Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 36. Southeast Asia Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 37. India Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 38. Australia Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 39. Latin America Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 40. Latin America Oncology Biosimilars Market Share by Country (2018-2034)
Figure 41. Mexico Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 42. Brazil Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 43. Middle East & Africa Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 44. Middle East & Africa Oncology Biosimilars Market Share by Country (2018-2034)
Figure 45. Turkey Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 46. Saudi Arabia Oncology Biosimilars Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 47. Celltrion Revenue Growth Rate in Oncology Biosimilars Business (2018-2023)
Figure 48. Biocon Revenue Growth Rate in Oncology Biosimilars Business (2018-2023)
Figure 49. Dr. Reddy’s Laboratories Revenue Growth Rate in Oncology Biosimilars Business (2018-2023)
Figure 50. STADA Arzneimittel AG Revenue Growth Rate in Oncology Biosimilars Business (2018-2023)
Figure 51. Intas Pharmaceuticals Revenue Growth Rate in Oncology Biosimilars Business (2018-2023)
Figure 52. Pfizer Revenue Growth Rate in Oncology Biosimilars Business (2018-2023)
Figure 53. Sandoz International Revenue Growth Rate in Oncology Biosimilars Business (2018-2023)
Figure 54. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Oncology Biosimilars Business (2018-2023)
Figure 55. Apotex Revenue Growth Rate in Oncology Biosimilars Business (2018-2023)
Figure 56. BIOCAD Revenue Growth Rate in Oncology Biosimilars Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries